Bulletin
Investor Alert

The Wall Street Journal Archives | Email alerts

July 26, 2018, 7:52 a.m. EDT

Biogen Alzheimer’s disease drug results impress, but more research still needed

Though the trial’s main finding was positive, results were overall mixed, causing Biogen shares to fall

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eisai Co. Ltd. ADR (ESALY)
  • X
    Biogen Inc. (BIIB)

or Cancel Already have a watchlist? Log In

By Peter Loftus


Getty Images

Eisai Co. and Biogen Inc. revealed new data showing their closely watched experimental drug slowed the worsening of Alzheimer’s disease, but some experts who saw the latest results said more testing is needed to validate whether the drug is truly providing a benefit.

Eisai /zigman2/quotes/202565502/delayed ESALY +0.71%  and Biogen /zigman2/quotes/201531540/composite BIIB -0.32%  said in early July that the drug, known as BAN2401, showed positive results in the mid-stage study but offered few details at the time. The news sent shares of both companies soaring on hopes that the industry may finally have found a drug that slows the underlying course of the memory-eroding disease, rather than temporarily improve symptoms as some current treatments do.

On Wednesday Eisai, which has led development of the drug, presented final results, saying early Alzheimer’s patients receiving the highest dose had 30% less decline than those taking a placebo 18 months after the start of treatment. The results, presented at the Alzheimer’s Association International Conference in Chicago, are based on an efficacy measure that Eisai developed, testing patients’ memory and ability to care for themselves.

Lynn Kramer, chief medical officer of Eisai’s neurology business group, called the results “fairly conclusive” and said the company has begun setting up meetings with drug regulators to discuss next steps, in hopes of receiving marketing approval.

An expanded version of this report can be seen at WSJ.com.

Popular on WSJ:

Trump’s Former Lawyer Michael Cohen Recorded Conversation About Stormy Daniels Payment With News Anchor

U.S., Europeans Agree to Iron Out Trade Differences

/zigman2/quotes/202565502/delayed
US : U.S.: OTC
$ 91.00
+0.64 +0.71%
Volume: 849.00
Sept. 18, 2020 9:30a
P/E Ratio
22.73
Dividend Yield
1.37%
Market Cap
$26.29 billion
Rev. per Employee
$543,512
loading...
/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 274.48
-0.89 -0.32%
Volume: 3.07M
Sept. 18, 2020 4:00p
P/E Ratio
8.04
Dividend Yield
N/A
Market Cap
$43.45 billion
Rev. per Employee
$1.55M
loading...

Get news alerts on Biogen Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.